

Utility contrast enhanced ultrasonography for detecting residual liver tumor early after transarterial chemoembolization: A diagnostic metanalysis

Made Vidyasti Laksita Wijaya, Kadek Adit Wiryadana

Buleleng, 2022-10-27

Introduction

Transarterial chemoembolization (TACE) is the recommended treatment of choice for intermediate stage HCCs.¹ The underlying principle of TACE is inducing tumor tissue hypoxia with the selective delivery of embolization particles together with a chemotherapeutic drug. TACE is still considered a palliative method, although it might achieve a complete therapeutic response, small numbers of malignant cells can escape necrosis.² Early evaluation and detection of those residual tumor warrant a chance for immediate repeat treatment.³⁻⁶ Thereby, the modality for early detection is paramount important. The most promising modality is the contrast-enhanced ultrasonography (CEUS). This study aimed to gather evidence for diagnostic performance of CEUS in detecting residual tumor within 24-72 hours after TACE treatment.

Methods

Literature Search

Data from literature up to September 2022 were searched from PubMed, Embase and Google scholar. The search term were combination of following: (1) hepatocellular carcinoma, liver carcinoma, liver cancer, hepatoma and HCC; (2) transarterial chemoembolization and TACE; and (3) contrast enhanced ultrasound, contrast enhanced ultrasonography and CEUS.

Study Selection

Studies were included in the analysis if they met the following inclusion criteria: (1) all participant received TACE treatment for hepatocellular carcinoma; (2) all participant had CEUS examination within 72 hours after TACE; (3) All participant underwent confirmation test after 1 month with Contrast Enhanced Computed Tomography (CECT) or Magnetic Resonance Imaging (MRI) or both; (4) The study included the absolute number of true-positive, true-negative, false-positive, false-negative or the value of sensitivity, specificity, positive predictive value and negative predictive value. The study excluded if met the following criteria: (1) the publication included a case report, reviews, or editorial; (2) the study did not report the sufficient parameter of the diagnostic performance about the index test of interest. Literature search and study selection were conducted by two authors (MVLW and KAW). Discrepancy, if any, were resolved by discussion and agreement.

Data Collection

The screened study were evaluated and the following data were collected: (1) author, publication date and study design; (2) study quality assessed by the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)⁷; (2) investigators (MVLW and KAW) independently performed a quality assessment of the included studies, and disagreements were resolved by discussion; (3) the data regarding true positive, false-positive, false-negative, and true-negative results gathered or calculated from each study

Risk of Bias and Quality Assessment

Risk of bias of the included study was assessed with QUADAS. Visualization for study heterogeneity, indicating for variations between studies, was presented with SROC and Cross-Hairs plots as well as calculation for I^2 statistics. If an I^2 indicate significant heterogeneity, data were pooled by random-effects model, otherwise it pooled by fixed-effects model.

Statistical Analysis

The collected data were tabulated in spreadsheet (Google Sheet) and analyzed in R statistical language (v 4.1.2)⁸ through Rstudio interface (RStudio Server 2022.02.3+492 for Ubuntu Bionic).^{9,10} Diagnostic metanalysis specific calculation conducted using Mada package.¹¹ The main analysis was focused on the pooled diagnostic parameter of CEUS early after TACE in detecting residual tumors. The pooled sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), negative likelihood ratio (NLR) and the diagnostic odds ratio were calculated using the suitable model in respect for the between study heterogeneity. The summary of diagnostic performance were presented in SROC curve. Additional R package used include rmarkdown for reproducible data calculation and manuscript preparation,¹² googlesheet4 for data bridging from Google Sheets to R,¹³ gtsummary for table generation,¹⁴ PRISMA2022 for PRISMA chart generation,¹⁵ and robvis for risk of bias plotting.¹⁶

Results

Search Results

A total of XX studies were identified by literature search. Studies were excluded after screened for title, abstract, or the entire full text. A total of four studies were suitable for the review and thus included in the metanalysis. A PRISMA flow diagram depicting the screening and review process is presented in the figure 1.¹⁷


Summary of the Included Studies

The included studies were mostly published within the last decade, starting from 2013 to 2021. The four studies were all prospective studies. The study sample size ranging from X to Y, involved X to Y nodules, both totalling at XXXX patients and YYYY nodules. The range of patients age were X to Y. The tumor size between x to y. Two studies examined the liver after two days post TACE, other studies one day and at the third day after TACE. The main reference examination were X, x studies include A examination, x studies include B examination, and x studies include C examination. The X study followed up the patients for X month with X examination at X month. X studies also conduct CT scan accompanying the standalone CEUS. One study by X et al., include a an image fusion of CEUS and CT scan.

```
## Descriptive summary of ceus with 4 primary studies.
## Confidence level for all calculations set to 95 %
## Using a continuity correction of 0.5 if applicable
##
## Diagnostic accuracies
##      sens  2.5% 97.5%  spec  2.5% 97.5%
## [1,] 0.682 0.511 0.814 0.905 0.803 0.957
## [2,] 0.948 0.846 0.984 0.808 0.537 0.938
## [3,] 0.900 0.660 0.977 0.635 0.444 0.791
## [4,] 0.790 0.619 0.897 0.955 0.679 0.995
##
## Test for equality of sensitivities:
## X-squared = 10.9525, df = 3, p-value = 0.012
## Test for equality of specificities:
## X-squared = 10.7727, df = 3, p-value = 0.013
##
```

```
##
## Diagnostic OR and likelihood ratios
##      DOR    2.5%    97.5% posLR  2.5%    97.5% negLR  2.5% 97.5%
## [1,] 20.455  6.517   64.198  7.190 3.140   16.466 0.352 0.212 0.583
## [2,] 76.440 11.698  499.492  4.929 1.615   15.047 0.064 0.019 0.222
## [3,] 15.632  2.418  101.038  2.463 1.444    4.201 0.158 0.034 0.739
## [4,] 79.154  4.078 1536.547 17.387 1.152  262.400 0.220 0.110 0.440
##
## Correlation of sensitivities and false positive rates:
##      rho  2.5 % 97.5 %
## 0.644 -0.832 0.991
```

Publication Bias and Heterogeneity




		Risk of bias domains				
		D1	D2	D3	D4	Overall
Study	Study 1					
	Study 2					
	Study 3					
	Study 4					


Domains:
D1: Patient selection.
D2: Index test.
D3: Reference standard.
D4: Flow & timing.


Judgement
 High
 Some concerns
 Low


Diagnostic Accuracy of CEUS and CECT



Specificity








```
## Call: reitsma.default(data = ceus)
##
## Bivariate diagnostic random-effects meta-analysis
## Estimation method: REML
##
## Fixed-effects coefficients
##           Estimate Std. Error      z Pr(>|z|) 95%ci.lb 95%ci.ub
## tsens.(Intercept)   1.747    0.497  3.513   0.000   0.773   2.722 ***
## tfpr.(Intercept)   -1.473    0.481 -3.062   0.002  -2.416  -0.530 **
## sensitivity         0.852      -      -      -      0.684   0.938
## false pos. rate     0.186      -      -      -      0.082   0.370
## ---
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
##
## Variance components: between-studies Std. Dev and correlation matrix
##           Std. Dev tsens  tfpr
## tsens     0.835 1.000    .
## tfpr     0.757 1.000 1.000
##
## logLik    AIC    BIC
##  8.576 -7.152 -6.755
##
## AUC: 0.899
## Partial AUC (restricted to observed FPRs and normalized): 0.771
##
## I2 estimates
```


Zhou and Dendukuri approach: 0 %
Holling sample size unadjusted approaches: 28.2 - 37.3 %
Holling sample size adjusted approaches: 1.5 - 2 %



Discussion

Summary of the Results

Limitations

Applications

Conclusion

Disclaimer

Funding

This study was not supported by third party funding

Conflict of Interest

All authors declare no conflict of interest.

Authors Contribution

Both MVLW and KAW share a proportional contribution in all phases of this study.

References

- 1 Kudo M. A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: Initial lenvatinib therapy with subsequent selective TACE. *Liver Cancer* 2019; **8**: 299–311.
- 2 Liapi E, Geschwind J-FH. Transcatheter arterial chemoembolization for liver cancer: Is it time to distinguish conventional from drug-eluting chemoembolization? *CardioVascular and Interventional Radiology* 2010; **34**: 37–49.
- 3 Wobser H, Wiest R, Salzberger B, Wohlgemuth WA, Stroszczynski C, Jung E-M. Evaluation of treatment response after chemoembolisation (TACE) in hepatocellular carcinoma using real time image fusion of contrast-enhanced ultrasound (CEUS) and computed tomography (CT) - Preliminary results. *Clinical Hemorheology and Microcirculation* 2014; **57**: 191–201.
- 4 Shiozawa K, Matsui T, Murakami T, Watanabe M, Maetani I. Predicting Therapeutic Efficacy of Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound. *Diagnostics (Basel, Switzerland)* 2021; **11**: 291.
- 5 Takizawa K, Numata K, Morimoto M, Kondo M, Nozaki A, Moriya S *et al.* Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. *European Journal of Radiology* 2013; **82**: 1471–1480.
- 6 Watanabe Y, Ogawa M, Kumagawa M, Hirayama M, Miura T, Matsumoto N *et al.* Utility of Contrast-Enhanced Ultrasound for Early Therapeutic Evaluation of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization. *Journal of Ultrasound in Medicine* 2020; **39**: 431–440.
- 7 Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Medical Research Methodology* 2003; **3**. doi:10.1186/1471-2288-3-25.
- 8 R Core Team. *R: A language and environment for statistical computing*. R Foundation for Statistical Computing: Vienna, Austria, 2021<https://www.R-project.org/>.
- 9 Rstudio. RStudio: Integrated Development for R. 2021.<http://www.rstudio.com/>.
- 10 Canonical. Ubuntu Server. 2021.https://wiki.ubuntu.com/FocalFossa/ReleaseNotes?_ga=2.202901329.1166669392.1642903327-1244252401.1642903327.
- 11 Doebler P, Sousa-Pinto B. *Mada: Meta-analysis of diagnostic accuracy*. 2022<https://CRAN.R-project.org/package=mada>.
- 12 Xie Y, Allaire JJ, Grolemond G. *R markdown: The definitive guide*. Chapman; Hall/CRC: Boca Raton, Florida, 2018<https://bookdown.org/yihui/rmarkdown>.
- 13 Bryan J. *googlesheets4: Access google sheets using the sheets API V4*. 2021<https://CRAN.R-project.org/package=googlesheets4>.
- 14 Sjoberg DD, Whiting K, Curry M, Lavery JA, Larmarange J. Reproducible summary tables with the gtsummary package. *The R Journal* 2021; **13**: 570–580.
- 15 Haddaway NR, Pritchard CC, McGuinness LA. *PRISMA2020: R package and ShinyApp for producing PRISMA 2020 compliant flow diagrams (version 0.0.2)*. 2021 doi:10.5281/zenodo.5082518.
- 16 McGuinness LA. Robvis: An r package and web application for visualising risk-of-bias assessments. 2019.<https://github.com/mcguinlu/robvis>.
- 17 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD *et al.* The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* 2021; : n71.

Abstract